ADMA Biologics (ADMA) Stock Statistics & Valuation Metrics

ADMA Biologics has a market cap or net worth of $4.53B. The enterprise value is $4.86B.

ADMA Biologics has 238,734,250 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADMA Biologics’s return on equity (ROE) is 0.57 and return on invested capital (ROIC) is 50.31%.

The current PE Ratio of ADMA Biologics is 22.0. ADMA Biologics’s PEG ratio is ―.

In the last 12 months, ADMA Biologics had revenue of 426.45M and earned 197.67M in profits. Earnings per share was 0.85.

In the last 12 months, operating cash flow was -14.24M and capital expenditures -586.86K, giving a free cash flow of -14.83M billion.

ADMA Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

ADMA Biologics upcoming earnings date is Nov 5, 2025, TBA (Confirmed).

ADMA Biologics as a current ratio of 5.97, with Debt / Equity ratio of 21.96%

In the past 12 months, ADMA Biologics has paid -71.96M in taxes.

ADMA Biologics EV to EBITDA ratio is 26.92, with an EV/FCF ratio of 36.12.

ADMA Biologics has $71.63M in cash and marketable securities with $82.01M in debt, giving a net cash position of $10.39M billion.

Gross margin is 52.55%, with operating margin of 32.59%, and net profit margin of 46.35%.

The average price target for ADMA Biologics is $33.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy